-Sinobiopharma to Market the World's First Perindopril in Capsule Form-
High blood pressure is a leading cause of stroke, heart attack and kidney failure and affects about a billion people worldwide. In
"High blood pressure affects nearly one in five Chinese adults during his lifetime (source: State Council of
Perindopril, used alone or in combination with other medications to treat high blood pressure, is the latest generation of a class of medications called angiotensin-converting enzyme (ACE) inhibitors. It supports circulation by preventing the production of chemicals that occur naturally in the body but constrict blood vessels.
The Company has received the Drug Certificate for Perindopril raw material (Certificate #2007S00493) from the Chinese State Food and Drug Administration, (SFDA), and is now awaiting GMP Certification. The Company has submitted its application to China's State Intellectual Property Office (SIPO) for a Chinese patent for Perindopril and its new drug compounds and obtained a receiving number (200810242989.1; "New Drug Compounds Containing Perindopril"). Sinobiopharma completed clinical trials for the capsule formulation in
Sinobiopharma has received approval from the SFDA to manufacture and market its new version of the anti-hypertensive drug, Perindopril, as well as its API. Prior to SFDA approval of Sinobiopharma's version, Servier (
About Sinobiopharma
Sinobiopharma Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in
FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
SOURCE Sinobiopharma, Inc.